James E. Early
Plus aucun poste en cours
Profil
James E.
Early joined Synageva BioPharma Corp.
in 2006 and currently serves as Senior Vice President of Finance and Administration.
Prior to joining Synageva BioPharma, he was Chief Financial Officer and Vice President of Finance for Anesthesiologists Associated, Inc. Previously, Mr. Early held various management positions at Zila Pharmaceuticals and Schein Pharmaceutical (now known as Watson).
He has over 10 years of experience in the pharmaceutical industry.
Mr. Early received a BBA degree in Accounting from the University of Notre Dame and an MBA from the University of California, Los Angeles Anderson School of Management.
He is a Certified Public Accountant.
Anciens postes connus de James E. Early
| Sociétés | Poste | Fin |
|---|---|---|
| Schein Pharmaceutical, Inc. | Corporate Officer/Principal | - |
| Anesthesiologists Associated, Inc. | Directeur Financier/CFO | - |
Zila Pharmaceuticals, Inc.
 Zila Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Part of TOLMAR Holding, Inc., Zila Pharmaceuticals, Inc. manufactures medicinal products. The company is based in Phoenix, AZ. | Corporate Officer/Principal | - |
Synageva BioPharma Corp. /Old/
 Synageva BioPharma Corp. /Old/ BiotechnologyHealth Technology Synageva BioPharma's ultimate goal is to improve patient lives by providing access to breakthrough novel, next generation (i.e. significantly improved), and certain follow on protein therapeutics. Synageva's proprietary platform technologies, including SEP™, provide a number of sustainable competitive advantages for developing and commercializing these therapeutics including: high expression levels, more efficient purification processes, significantly reduced costs of production, rapid scalability, and consistency of end product. Its platform has already demonstrated its ability to produce a wide array of human therapeutic proteins including monoclonal antibodies (mAbs), cytokines, and other biotherapeutics. It has multiple compounds in development, including 2 monoclonal antibodies with enhanced ADCC activity, novel therapeutic proteins, and several cytokines including one with unique efficacy advantages. The commercialization strategy for these product candidates is designed to maximize its ability to rapidly develop and bring them to market so that they can address patients' unmet medical needs. The key elements of the strategy are to: 1. Establish partnerships to co-develop and commercialize select product candidates in large specialty markets 2. Independently develop and commercialize select novel product candidates that target high value orphan specialty markets 3. Establish partnerships to express proteins from other companies wanting to leverage the unique glycosylation advantages and other characteristics of the SEP™. | Directeur Financier/CFO | - |
Formation de James E. Early
| University of Notre Dame | Undergraduate Degree |
| UCLA School of Law | Masters Business Admin |
Expériences
Fonctions occupées
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Synageva BioPharma Corp. /Old/
Synageva BioPharma Corp. /Old/ BiotechnologyHealth Technology Synageva BioPharma's ultimate goal is to improve patient lives by providing access to breakthrough novel, next generation (i.e. significantly improved), and certain follow on protein therapeutics. Synageva's proprietary platform technologies, including SEP™, provide a number of sustainable competitive advantages for developing and commercializing these therapeutics including: high expression levels, more efficient purification processes, significantly reduced costs of production, rapid scalability, and consistency of end product. Its platform has already demonstrated its ability to produce a wide array of human therapeutic proteins including monoclonal antibodies (mAbs), cytokines, and other biotherapeutics. It has multiple compounds in development, including 2 monoclonal antibodies with enhanced ADCC activity, novel therapeutic proteins, and several cytokines including one with unique efficacy advantages. The commercialization strategy for these product candidates is designed to maximize its ability to rapidly develop and bring them to market so that they can address patients' unmet medical needs. The key elements of the strategy are to: 1. Establish partnerships to co-develop and commercialize select product candidates in large specialty markets 2. Independently develop and commercialize select novel product candidates that target high value orphan specialty markets 3. Establish partnerships to express proteins from other companies wanting to leverage the unique glycosylation advantages and other characteristics of the SEP™. | Health Technology |
| Anesthesiologists Associated, Inc. | |
Zila Pharmaceuticals, Inc.
Zila Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Part of TOLMAR Holding, Inc., Zila Pharmaceuticals, Inc. manufactures medicinal products. The company is based in Phoenix, AZ. | Health Technology |
| Schein Pharmaceutical, Inc. | Health Technology |
